Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Nat Genet. 2011 Feb 6;43(3):246–252. doi: 10.1038/ng.764

Table 1. Association results and in silico analyses for the 18 previously confirmed (P<5×10-8) ulcerative colitis (UC) loci.

Left-right association boundaries are given for each index SNP (see Online Methods). RAF = risk allele frequency. OR is estimated using the meta-analysis cohort only. Known associations represent phenotypes previously associated with the locus at P<5×10-8). AS = ankylosing spondylitis, Ast = Asthma, BD = Behçet’s disease, CD = Crohn’s disease, CeD = celiac disease, Graves’ disease = GD, HL = Hodgkin’s lymphoma, MS = multiple sclerosis, PBC = primary biliary sclerosis, Ps = psoriasis, RA = rheumatoid arthritis, SLE = systemic lupus erythematosus, T1D = type 1 diabetes and WBC = white blood cell count. Candidate genes of interest are listed. Those in bold were highlighted by in silico analyses (GRAIL connectivity and/or presence of an eQTL or nonsynonymous SNP. See Online Methods and Supplementary Table 7 for more details).

dbSNP ID Chr. Left-right(Mb) Risk Allele Allele frequency in controls P-value (meta) OR (95% CI) Association reported with other phenotypes Positional candidate genes of interest
rs6426833 1p36 19.93-20.18 A 0.541 3.93 × 10-35 1.30 (1.25-1.35)
rs11209026 1p31 67.30-67.54 G 0.935 5.12 × 10-28 1.74 (1.57-1.92) CD, AS, BD, Ps IL23R
rs1801274 1q23 159.54-159.91 A 0.505 2.16 × 10-20 1.21 (1.16-1.26) SLE FCGR2A, FCGR2B, HSPA6
rs3024505 1q32 204.85-205.11 A 0.159 5.76 × 10-17 1.25 (1.19-1.32) CD, BD, SLE, T1D IL10, IL19
rs7608910 2p16 60.76-61.87 G 0.390 1.70 × 10-14 1.19 (1.14-1.24) CD, CeD, RA PUS10
rs4676406 2q37 241.20-241.32 T 0.516 8.32 × 10-11 1.14 (1.09-1.18) GPR35
rs9822268 3p21 48.14-51.77 A 0.302 1.60 × 10-17 1.21 (1.16-1.26) CD MST1, UBA7, APEH, AMIGO3, GMPPB, BSN
rs17388568 4q27 123.20-123.78 A 0.273 9.49 × 10-7 1.12 (1.07-1.17) CeD, T1D IL21, IL2, ADAD1
rs11739663 5p15 0.48-0.80 T 0.767 2.80 × 10-8 1.15 (1.09-1.21) EXOC3
rs9268853 6p21 31.49-33.01 T 0.661 1.35 × 10-55 1.40 (1.34-1.47) CD, CeD, GrD, MS, PBC, RA, T1D HLA-DRB5, HLA-DQA1, HLA-DRB1, HLA-DRA, BTNL2
rs4510766 7q22 107.20-107.39 A 0.559 2.00 × 10-16 1.20 (1.15-1.26)
rs6584283 10q24 101.25-101.33 T 0.472 8.46 × 10-21 1.21 (1.16-1.26) CD
rs7134599 12q14 66.72-66.92 A 0.385 1.06 × 10-16 1.19 (1.14-1.24) IFNG, IL26
rs6499188 16q22 66.98-67.40 A 0.749 3.97 × 10-8 1.14 (1.09-1.20) ZFP90
rs2872507 17q12 34.62-35.51 A 0.463 5.44 × 10-11 1.15 (1.10-1.19) CD, Ast, PBC, T1D, WBC IKZF3, ORMDL3, IKZF3, PNMT, ZPBP2, GSDML
rs6017342 20q13 42.49-42.70 C 0.538 1.09 × 10-20 1.20 (1.15-1.26) HDL SERINC3
rs2836878 21q22 39.34-39.41 G 0.738 1.86 × 10-22 1.25 (1.20-1.32) AS
rs5771069 22q13 48.70-48.83 G 0.515 1.87 × 10-7 1.11 (1.07-1.16) PIM3, IL17REL
HHS Vulnerability Disclosure